Study of HMB-002 for von Willebrand disease
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests a new medicine called HMB-002 for people with von Willebrand disease. It aims to see if the drug can help control bleeding without needing regular preventive treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be diagnosed with von Willebrand disease (VWD) by a doctor.
- Your weight must be between 110 and 265 pounds (50 to 120 kg).
- You cannot be on regular preventive treatment for bleeding (except for certain parts of the study).
- You must have low VWF activity (below 50 IU/dL) and low factor VIII (below 70 IU/dL).
- You cannot have a history of blood clots or conditions that increase clot risk.
- You must be at least 16 years old (some groups require 18 or older) and under 70.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new treatment for people with certain types of Von Willebrand disease (Type 1 or 2A) who have frequent bleeding problems. It aims to see if the treatment can help reduce these bleeding episodes.
This trial tests a new medicine called BT200 (rondaptivon pegol) to see if it can safely help people with type 2B von Willebrand disease who have low platelets and recent bleeding problems.
This trial tests a new drug called VGA039 that is injected under the skin to prevent bleeding episodes in people with von Willebrand disease. It is for those who bleed frequently and are not currently using regular preventive treatments.
This Phase 3 trial tests an recombinant version of the von Willebrand factor (rVWF) for people with severe von Willebrand disease (VWD) living in China. It aims to see if the drug can safely control bleeding and help those who need regular clotting factor treatments.
This Phase 3 trial tests vonicog alfa (an rVWF treatment) to prevent and control bleeding in children with severe von Willebrand disease (vWD). You may be able to join if your child has severe vWD and has been on prior clotting factor treatment with ongoing bleeding despite that care.
This study tests whether SR604, a new injection given under the skin, can reduce bleeding episodes in people with von Willebrand disease (a condition where blood doesn't clot properly). The trial will measure how well it works, how safe it is, and how your body processes it.
Hear when a new Von Willebrand Disease (VWD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.